In addition, animal models have provided further validation, demonstrating that TLCD1/2 knockout leads to the development of fatty liver disease and a reduction in the incidence of non-alcoholic steatohepatitis (NASH) (Petkevicius et al., 2022). This evidence concerns the gene TLCD1 and metabolic dysfunction-associated steatohepatitis.